AI can determine eczema severity from images, with results correlating with severity assigned by board-certified clinicians.

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.

The FDA has announced its plan for systematically reviewing food additives already commercially available for the first time.

A new COVID-19 variant, NB.1.8.1, has spread in the Mediterranean, Southeast Asia, and Western Pacific regions.

Conversations in Dermatology: 2025 will focus on clinical challenges and recent advances that health care providers who manage chronic pruritic conditions should know.

Most clinicians see adolescents with substance use disorders monthly, while about half report screening for them at every visit.

Training for those who administer cosmetic injections is lacking, despite significant growth in demand for fillers in the aesthetic medicine industry.

Patients with varicose veins have a higher risk for all-cause dementia, while treatment of varicose veins is tied to a lower risk for vascular dementia.

The FDA has ordered Pfizer and Moderna to amend the warning labels on their COVID-19 vaccines with risk of myocarditis and pericarditis.

Anti-OX40 medications have been associated with positive efficacy and safety outcomes for the treatment of atopic dermatitis.

Symptoms, lesion locations, and morphology are among the features clinicians may use to distinguish hand eczema from hand psoriasis in patients.